Below is Validea's guru fundamental report for BRIDGEBIO PHARMA INC (BBIO). Of the 22 guru strategies we follow, BBIO rates highest using our Contrarian Investor model based on the published strategy of David Dreman. BRIDGEBIO PHARMA INC (BBIO) is a mid-cap growth stock in the Biotechnology & Drugs industry. At the time Dreman published Contrarian Investment Strategies: The Next Generation, the fund had been ranked number one in more time periods than any of the 3,175 funds in Lipper's database. Additional Research LinksTop Healthcare StocksDividend Aristocrats 2024Wide Moat StocksRecession Proof StocksHigh Insider Ownership StocksFactor-Based Stock PortfoliosAbout Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends.

Source: Forbes November 07, 2024 21:12 UTC